# A Study to Evaluate the SYH2053 Injection in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)

> **NCT07465263** · PHASE3 · NOT_YET_RECRUITING · sponsor: **CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.** · enrollment: 135 (estimated)

## Conditions studied

- Heterozygous Familial Hypercholesterolemia (HeFH)

## Interventions

- **DRUG:** SYH2053 Injection
- **DRUG:** Placebo Injection

## Key facts

- **NCT ID:** NCT07465263
- **Lead sponsor:** CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-31
- **Primary completion:** 2028-02-28
- **Final completion:** 2028-05-31
- **Target enrollment:** 135 (ESTIMATED)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07465263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07465263, "A Study to Evaluate the SYH2053 Injection in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07465263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*